Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Public ClinicalTrials.gov record NCT02635724. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Single-arm, Open-label, Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of Intravenous Peramivir in Elderly Subjects With Acute Uncomplicated Influenza Infection and in Subjects With Acute Uncomplicated Influenza Infection at Higher Risk for Influenza Complications
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. All subjects will receive IV peramivir.
Study identification
- NCT ID
- NCT02635724
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 74 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2015
- Primary completion
- Mar 31, 2018
- Completion
- Aug 31, 2018
- Last update posted
- Mar 22, 2021
2015 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Peramivir Investigational Site | Brooksville | Florida | — | — |
| Peramivir Investigational Site | Lakeland | Florida | — | — |
| Peramivir Investigational Site | Miami | Florida | — | — |
| Peramivir Investigational Site | St. Petersburg | Florida | — | — |
| Peramivir Investigational Site | Tampa | Florida | — | — |
| Peramivir investigative site | Indianapolis | Indiana | — | — |
| Peramivir investigative site | Detroit | Michigan | — | — |
| Peramivir Investigational Site | Dayton | Ohio | — | — |
| Peramivir investigative site | Smithfield | Pennsylvania | — | — |
| Peramivir Investigational Site | Houston | Texas | — | — |
| Peramivir Investigative Site | San Antonio | Texas | — | — |
| Peramivir investigative site | Splendora | Texas | — | — |
| Peramivir Investigational Site | Draper | Utah | — | — |
| Peramivir Investigational Site | Salt Lake City | Utah | — | — |
| Peramivir investigative site | South Jordan | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02635724, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2021 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02635724 live on ClinicalTrials.gov.